Active	Status	Sponsor type	Region	Phase	Filter
10 Active 1 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Davis, Margot
ATRIUM, NCT05335928: Abatacept in Immune Checkpoint Inhibitor Myocarditis	Recruiting	3	390	Canada, US	Abatacept plus, Orencia, Placebo	Massachusetts General Hospital, Bristol-Myers Squibb	Myocarditis Acute, Cancer	11/26	04/27
Gupta, Dipti
ATRIUM, NCT05335928: Abatacept in Immune Checkpoint Inhibitor Myocarditis	Recruiting	3	390	Canada, US	Abatacept plus, Orencia, Placebo	Massachusetts General Hospital, Bristol-Myers Squibb	Myocarditis Acute, Cancer	11/26	04/27
NCT06355661: A Study for Assessing the Efficacy and Safety ParActin® in Individuals With Upper Respiratory Tract Infections	Recruiting	N/A	120	RoW	ParActin®: 300 mg + MCC: 100 mg (± 10%) per Capsule, MCC: 400 mg (± 10%) per Capsule	Vedic Lifesciences Pvt. Ltd.	Upper Respiratory Tract Infections	07/24	07/24
NCT05835375: A Study to Evaluate the Efficacy of EQ-778 on Upper Respiratory Tract Health Status in Healthy Adults	Recruiting	N/A	374	RoW	EQ-778, Placebo	Vedic Lifesciences Pvt. Ltd.	Upper Respiratory Tract Infection	04/24	04/24
Powell, Madeleine
No trials found